Reference Detail

Ref Type
PMID
Authors Ravit Geva, Mark Voskoboynik, Amy M Beebe, Jennifer Gwo, Konstantin Dobrenkov, Elliot Chartash, Georgina V. Long
Title First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
Journal J Clin Oncol
Vol
Issue
Date
URL http://abstracts.asco.org/214/AbstView_214_219785.html
Abstract Text J Clin Oncol 36, 2018 (suppl; abstr 3029)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
MK-1248 MK-1248 0 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
MK-1248 MK-1248 is a monoclonal antibody binds to and activates glucocorticoid-induced TNF receptor (GITR), resulting in activation of anti-tumor immunity (J Clin Oncol 36, 2018 (suppl; abstr 3029)).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable MK-1248 + Pembrolizumab Phase I Actionable In a Phase I trial, MK-1248 in combination with Keytruda (pembrolizumab) resulted in complete response in 6% (1/17) and partial response in 12% (2/17) of patients with advanced solid tumor (J Clin Oncol 36, 2018 (suppl; abstr 3029); NCT02553499). detail...